Live
FierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery systemBioWorldNME Digest: Q1 2026FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteranBioWorldNew York University identifies new analogues of mannose-6-phosphateBioWorldAvelos Therapeutics synthesizes new PARG inhibitorsBioWorldSimcere Zaiming Pharmaceutical discovers new MAPK inhibitorsLabiotechEight oncology deals in 2026 spotlight where industry leaders are betting bigEndpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseasesFierceBiotechHow RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execBioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
FierceBiotech 21 avr. 2026

Replimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection

Replimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection

Original
Contenu indisponible. Consultez la source originale.